Trials / Completed
CompletedNCT04094415
A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Italy, as Part of Local Clinical Practice
SURE ITALY: A Multi-centre, Prospective, Non-interventional Study Investigating the Effectiveness of Once-weekly Subcutaneous Semaglutide in a Real World Adult Population With Type 2 Diabetes
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 581 (actual)
- Sponsor
- Novo Nordisk A/S · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to collect information on how semaglutide works in real world patients. Participants will get semaglutide prescribed to them by their doctor. The study will last for about 6 to 8 months. Participants will be asked to complete some questionnaires about their health and your diabetes treatment. Participants will complete these during their normally scheduled visits with their doctor.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Semaglutide | Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.The decision to initiate treatment with semaglutide is at the treating physician's discretion, and clearly separated from the decision to include the patient in the study. |
Timeline
- Start date
- 2019-10-28
- Primary completion
- 2021-07-28
- Completion
- 2021-07-28
- First posted
- 2019-09-19
- Last updated
- 2023-02-23
Locations
39 sites across 1 country: Italy
Source: ClinicalTrials.gov record NCT04094415. Inclusion in this directory is not an endorsement.